Our Pipeline Products
Making Medicine Smarter Through Transdermal Patches
1- Ondansetron Transdermal Patch for Pregnancy-Induced Nausea and Vomiting
2- Apixaban Transdermal Patch for
Atrial Fibrillation
1
Pregnancy-induced nausea and vomiting (PINV) affects up to 85% of pregnant women (2-3 million/year), typically for 10-15 weeks or longer.
While most pregnant women can tolerate their symptoms with dietary modifications or the approved pyridoxine + doxylamine combination, a sizable minority (10-20%) require more effective medication. The annual US economic impact of PINV – therapeutic interventions, lost workdays and even hospitalizations if patients are inadequately treated -- is considerable and may exceed $1 Billion. Ondansetron, while not approved for use in PINV, has been used off-label in this condition for many years; published studies support its effectiveness and it remains a drug of choice amongst many Obstetricians, yet oral administration multiple times daily can be challenging during intense periods of nausea. InteguRx seeks to cimcumvent the need for oral medication in PINV by developing a transdermal ondansetron patch for which it hopes to seek regulatory approval. Our patch is now being prepared for IND-enabling studies, after which we hope to commence clinical trials.
2
Between 50,000-90,000 Atrial Fibrillation (AF) patients may experience major bleeding events on oral apixaban each year, including hemorrhagic strokes and GI bleeds.
Atrial Fibrillation (AF) is a common cardiac arrhythmia that increases one’s risk of suffering a thrombotic stroke severalfold. There are projected to be 12.1 Million AF patients in the US by 2030. Between 40-70% of AF patients are now treated with long-term anticoagulation; the most prescribed of the Direct Oral Anticoagulants (DOACs) is apixaban (Eliquis®). Evidence suggests that the twice-daily peak concentrations of apixaban which follow each oral dose could be a contributing factor to bleeding adverse events, including hemorrhagic strokes. InteguRx Therapeutics is developing a transdermal patch that will deliver relatively constant levels of apixaban to the circulation for 3-7 days, without the plasma peaks associated with oral administration, with the goal of potentially decreasing the occurrence of major bleeding events on apixaban therapy. Our patch is now being optimized for delivery of the therapeutic dose of apixaban; we expect to then perform the requisite preclinical dermal safety studies to enable us to file an IND and proceed with clinical investigations.
